Market Currents
Goldman says the court ruling against Par Pharmaceutical (PRX -1.3%) regarding patents covering...
-
Wednesday, May 30, 2012, 12:48 PM ETGoldman says the court ruling against Par Pharmaceutical (PRX -1.3%) regarding patents covering Lovaza eliminates a key upside opportunity, adding that the extent of the impact on growth is unclear at this point. The firm maintains its Neutral rating on the shares.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
